Do analysts prefer CVKD or BFRI?

Cadrenal Therapeutics currently has a consensus target price of $13.00, suggesting a potential upside of 1,203.91%. Given Cadrenal Therapeutics' higher probable upside, equities research analysts plainly believe Cadrenal Therapeutics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor CVKD or BFRI?

In the previous week, Biofrontera had 3 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 7 mentions for Biofrontera and 4 mentions for Cadrenal Therapeutics. Biofrontera's average media sentiment score of 0.88 beat Cadrenal Therapeutics' score of 0.55 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biofrontera 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CVKD or FNCH?

Cadrenal Therapeutics presently has a consensus target price of $13.00, suggesting a potential upside of 1,203.91%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cadrenal Therapeutics is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, CVKD or FNCH?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$4.90 N/A Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A

Is CVKD or FNCH more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -406.41% -273.80% Finch Therapeutics Group N/A -69.14% -26.92%

Which has better valuation and earnings, CVKD or CABR?

Caring Brands is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$4.90 N/A Caring Brands N/A N/A -$6.28M -$0.74 N/A

Is CVKD or CABR more profitable?

Cadrenal Therapeutics' return on equity of -406.41% beat Caring Brands' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -406.41% -273.80% Caring Brands N/A -1,153.12% -322.63%

Do analysts recommend CVKD or PBM?

Cadrenal Therapeutics presently has a consensus price target of $13.00, indicating a potential upside of 1,203.91%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cadrenal Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, CVKD or PBM?

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$4.90 N/A Psyence Biomedical N/A N/A -$6.94M $25.34 0.18

Is CVKD or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -406.41% -273.80% Psyence Biomedical N/A N/A N/A

Which has higher earnings and valuation, CVKD or ADIL?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$4.90 N/A Adial Pharmaceuticals N/A N/A -$7.98M -$14.73 N/A

Is CVKD or ADIL more profitable?

Adial Pharmaceuticals' return on equity of -203.87% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -406.41% -273.80% Adial Pharmaceuticals N/A -203.87% -512.41%

Cadrenal Therapeutics (CVKD) Competitors

$1.03 +0.03 (+3.01%)

As of 02:26 PM Eastern

Compare

CVKD vs. BFRI, FNCH, CABR, PBM, and ADIL

Should you buy Cadrenal Therapeutics stock or one of its competitors? Cadrenal Therapeutics's main competitors and comparable companies include Biofrontera (BFRI), Finch Therapeutics Group (FNCH), Caring Brands (CABR), Psyence Biomedical (PBM), and Adial Pharmaceuticals (ADIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cadrenal Therapeutics compare to Biofrontera?

Cadrenal Therapeutics (NASDAQ:CVKD) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Biofrontera had 3 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 7 mentions for Biofrontera and 4 mentions for Cadrenal Therapeutics. Biofrontera's average media sentiment score of 0.88 beat Cadrenal Therapeutics' score of 0.55 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biofrontera	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cadrenal Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Biofrontera	-13.78%	-145.81%	-31.30%

Biofrontera has higher revenue and earnings than Cadrenal Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Biofrontera	$41.71M	0.32	-$10.54M	-$0.45	N/A

Cadrenal Therapeutics has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Cadrenal Therapeutics currently has a consensus target price of $13.00, suggesting a potential upside of 1,203.91%. Given Cadrenal Therapeutics' higher probable upside, equities research analysts plainly believe Cadrenal Therapeutics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Biofrontera beats Cadrenal Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Finch Therapeutics Group?

Cadrenal Therapeutics (NASDAQ:CVKD) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 0 mentions for Finch Therapeutics Group. Cadrenal Therapeutics' average media sentiment score of 0.55 beat Finch Therapeutics Group's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
Finch Therapeutics Group	Neutral

Cadrenal Therapeutics presently has a consensus target price of $13.00, suggesting a potential upside of 1,203.91%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cadrenal Therapeutics is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Finch Therapeutics Group's return on equity of -69.14% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Cadrenal Therapeutics has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Cadrenal Therapeutics beats Finch Therapeutics Group on 8 of the 12 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Caring Brands?

Cadrenal Therapeutics (NASDAQ:CVKD) and Caring Brands (NASDAQ:CABR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Cadrenal Therapeutics' return on equity of -406.41% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Caring Brands	N/A	-1,153.12%	-322.63%

Caring Brands is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Caring Brands	N/A	N/A	-$6.28M	-$0.74	N/A

Cadrenal Therapeutics currently has a consensus target price of $13.00, suggesting a potential upside of 1,203.91%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cadrenal Therapeutics is more favorable than Caring Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Caring Brands. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 2 mentions for Caring Brands. Caring Brands' average media sentiment score of 1.44 beat Cadrenal Therapeutics' score of 0.55 indicating that Caring Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
Caring Brands	Positive

7.9% of Cadrenal Therapeutics shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 14.6% of Caring Brands shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cadrenal Therapeutics beats Caring Brands on 7 of the 11 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Psyence Biomedical?

Cadrenal Therapeutics (NASDAQ:CVKD) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Psyence Biomedical. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 2 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.39 beat Cadrenal Therapeutics' score of 0.55 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
Psyence Biomedical	Positive

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cadrenal Therapeutics presently has a consensus price target of $13.00, indicating a potential upside of 1,203.91%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cadrenal Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Psyence Biomedical	N/A	N/A	N/A

Cadrenal Therapeutics has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.18

Summary

Cadrenal Therapeutics and Psyence Biomedical tied by winning 6 of the 12 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Adial Pharmaceuticals?

Cadrenal Therapeutics (NASDAQ:CVKD) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Cadrenal Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A

In the previous week, Cadrenal Therapeutics had 3 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.82 beat Cadrenal Therapeutics' score of 0.55 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
Adial Pharmaceuticals	Very Positive

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 8.0% of Adial Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Adial Pharmaceuticals' return on equity of -203.87% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Adial Pharmaceuticals	N/A	-203.87%	-512.41%

Cadrenal Therapeutics presently has a consensus price target of $13.00, suggesting a potential upside of 1,203.91%. Adial Pharmaceuticals has a consensus price target of $8.33, suggesting a potential upside of 153.29%. Given Cadrenal Therapeutics' higher possible upside, equities analysts plainly believe Cadrenal Therapeutics is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Cadrenal Therapeutics and Adial Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVKD vs. The Competition

Export

Metric	Cadrenal Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.78M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.22	807.81	275.40	25.37
Price / Sales	N/A	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	0.91	9.21	10.55	5.95
Net Income	-$13.24M	$2.84B	$3.50B	$380.75M
7 Day Performance	9.02%	-4.00%	-3.92%	-3.96%
1 Month Performance	N/A	-8.07%	-8.30%	-6.81%
1 Year Performance	-92.48%	-5.86%	2.35%	-4.58%

Cadrenal Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVKD Cadrenal Therapeutics	2.8417 of 5 stars	$1.03 +3.0%	$13.00 +1,165.8%	-92.9%	$3.78M	N/A	N/A	5	Gap Up
BFRI Biofrontera	1.7452 of 5 stars	$0.93 +4.6%	N/A	-5.3%	$13.23M	$46.18M	N/A	94	Analyst Forecast Short Interest Decrease
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
CABR Caring Brands	0.8527 of 5 stars	$1.25 +10.6%	N/A	N/A	$11.72M	N/A	N/A	3	Positive News Short Interest Decrease Gap Down
PBM Psyence Biomedical	1.584 of 5 stars	$5.02 -1.2%	N/A	-79.6%	$11.65M	N/A	0.20	12	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVKD) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. BFRI, FNCH, CABR, PBM, and ADIL

How does Cadrenal Therapeutics compare to Biofrontera?

Summary

How does Cadrenal Therapeutics compare to Finch Therapeutics Group?

Summary

How does Cadrenal Therapeutics compare to Caring Brands?

Summary

How does Cadrenal Therapeutics compare to Psyence Biomedical?

Summary

How does Cadrenal Therapeutics compare to Adial Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. BFRI, FNCH, CABR, PBM, and ADIL

How does Cadrenal Therapeutics compare to Biofrontera?

Do institutionals and insiders believe in CVKD or BFRI?

Does the media favor CVKD or BFRI?

Is CVKD or BFRI more profitable?

Which has higher earnings and valuation, CVKD or BFRI?

Which has more risk and volatility, CVKD or BFRI?

Do analysts prefer CVKD or BFRI?

Summary

How does Cadrenal Therapeutics compare to Finch Therapeutics Group?

Which has stronger earnings & valuation, CVKD or FNCH?

Does the media prefer CVKD or FNCH?

Do analysts recommend CVKD or FNCH?

Is CVKD or FNCH more profitable?

Which has more volatility and risk, CVKD or FNCH?

Do institutionals & insiders hold more shares of CVKD or FNCH?

Summary

How does Cadrenal Therapeutics compare to Caring Brands?

Is CVKD or CABR more profitable?

Which has better valuation and earnings, CVKD or CABR?

Do analysts prefer CVKD or CABR?

Does the media prefer CVKD or CABR?

Do institutionals & insiders have more ownership in CVKD or CABR?

Summary

How does Cadrenal Therapeutics compare to Psyence Biomedical?

Does the media prefer CVKD or PBM?

Do institutionals and insiders believe in CVKD or PBM?

Do analysts recommend CVKD or PBM?

Is CVKD or PBM more profitable?

Which has more volatility & risk, CVKD or PBM?

Which has preferable valuation & earnings, CVKD or PBM?

Summary

How does Cadrenal Therapeutics compare to Adial Pharmaceuticals?

Which has more risk and volatility, CVKD or ADIL?

Which has higher earnings and valuation, CVKD or ADIL?

Does the media refer more to CVKD or ADIL?

Do institutionals & insiders have more ownership in CVKD or ADIL?

Is CVKD or ADIL more profitable?

Do analysts recommend CVKD or ADIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools